Iowa Juvenile Crime Prevention Community Grant Fund, 2000

The Division of Criminal & Juvenile Justice Planning, as a part of its duties to administer Iowa’s Juvenile Crime Prevention Community Grant Fund, compiled the information contained in this report. Persons involved in the preparation of this report include Eric Sage, Sonya Wendell, and Richard Moore. Much of the report’s descriptions of community projects was adapted from narrative information contained in the applications and progress reports of agencies and units of government throughout the state that are participating in the Juvenile Crime Prevention Community Grant Fund

Pediatric Obesity: Influence on Drug Dosing and Therapeutics

Obesity is an ongoing global health concern and has only recently been recognized as a chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US children and adolescents. Severe obesity (³120% of the 95th percentile of BMI-for-age, or a BMI of ³35 kg/m2) is the fastest growing subgroup and now approaches 6% of all US youth. Health consequences (e.g., type 2 diabetes, coronary heart disease) are related in a dose-dependent manner to severity of obesity. Since therapeutic interventions are less effective in severe obesity, prevention is a high priority. Treatment plans involving combinations of behavioral therapy, nutrition and exercise achieve limited success. Only one drug, orlistat, is FDA-approved for long-term obesity management in adolescents 12 years and older. As part of comprehensive medication management, clinicians should consider the propensity for a given drug to aggravate weight gain and to consider alternatives that minimize weight impact. Medication management must take into account developmental changes as well as pathophysiology of obesity and comorbidities. Despite expanding insight into obesity pathophysiology, there are gaps in its translation to therapeutic application. The historical construct of obesity as simply a fat storage disorder is fundamentally inaccurate. The approach to adjusting doses based solely on body size and extrapolating from therapeutic knowledge of adult obesity may be based on assumptions that are not fully substantiated. Classes of drugs commonly prescribed for comorbidities associated with obesity should be prioritized for clinical research evaluations aimed at optimizing dosing regimens in pediatric obesity

Addiction: A big challenge of social security in Iran

Due to special conditions of Iran; i.e., neighboring to major centers of drug production in Afghanistan during the last few decades, it was the passageway of the drug to Europe. Moreover, because of appropriate context of social, economic and cultural situations, there was an increased addiction and drug trafficking in Iran. It is obvious that a lot of people would be involved directly and indirectly with drugs; so the drug has become a major problem in Iranian society, especially in the provinces near Afghanistan and Pakistan borders. The reports have indicated an increasing spread of drug addiction in Iran. Addiction among all social classes and occupational groups, age and sex, are raised. In fact, an important part of social problems, directly or indirectly related to drug dependence. Therefore, prevention of addiction as the basis of many diseases is vital priority for Iran. Fair distribution of facilities and services in society and equal opportunities for all members of society can legitimately, step forward in to deal with social ills such as addiction

Relating adults' lives and learning: participation and engagement in different settings

This report shows how an understanding of language, literacy andnumeracy as social practices can help practitioners to take account oflearners' lives. It demonstrates how people's histories, currentcircumstances and imagined futures can shape their learning andaffect their level of engagement. The study is based on the research ofthe Adult Learners' Lives project in community settings in Blackburn,Lancaster and Liverpool

Cell death and life in cancer: mathematical modeling of cell fate decisions

Tumor development is characterized by a compromised balance between cell life and death decision mechanisms, which are tighly regulated in normal cells. Understanding this process provides insights for developing new treatments for fighting with cancer. We present a study of a mathematical model describing cellular choice between survival and two alternative cell death modalities: apoptosis and necrosis. The model is implemented in discrete modeling formalism and allows to predict probabilities of having a particular cellular phenotype in response to engagement of cell death receptors. Using an original parameter sensitivity analysis developed for discrete dynamic systems, we determine the critical parameters affecting cellular fate decision variables that appear to be critical in the cellular fate decision and discuss how they are exploited by existing cancer therapies

The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey

I examine the effect of pharmaceutical innovation on the functional status of nursing home residents using cross-sectional, patient-level data from the 2004 National Nursing Home Survey. This was the first public-use survey of nursing homes that contains detailed information about medication use, and it contains better data on functional status than previous surveys. Residents using newer medications and a higher proportion of priority-review medications were more able to perform all five activities of daily living (ADLs), controlling for age, sex, race, marital status, veteran status, where the resident lived prior to admission, primary diagnosis at the time of admission, up to 16 diagnoses at the time of the interview, sources of payment, and facility fixed effects. The ability of nursing home residents to perform activities of daily living is positively related to the number of “new” (post-1990) medications they consume, but unrelated to the number of old medications they consume. If 2004 nursing home residents had used only old medications, the fraction of residents with all five ADL dependencies would have been 58%, instead of 50%. During the period 1990-2004, pharmaceutical innovation reduced the functional limitations of nursing home residents by between 1.2% and 2.1% per year.

Evolution of an Idea

An in-depth look at how students learn, including what sparks their interest in a research project and how professors assist them on the path of discovery

The State of Black Immigrants Part II: Black Immigrants in the Mass Criminalization System

Black immigrants are one of the fastest growing demographics in the United States. Nonetheless, this group remains a novelty in the broader immigration discourse. This report aims to elevate the conditions facing Black immigrants in the United States, drawing particular attention to their experience in the criminal law and immigration systems. This report argues that like African-Americans, Black immigrants experience disparate, often negative, outcomes within various social and economic structures in the U.S., including the country's mass criminalization and immigration enforcement regimes

The Promise of Priority Review Vouchers as a Legislative Tool to Encourage Drugs for Neglected Diseases

Despite the intellectual property system’s success in promoting the economic well-being of the United States, this system has not achieved all socially valuable ends. Insufficient treatments are applied both to diseases endemic in developing countries, such as malaria, and rare diseases, such as rare childhood cancers. Several legislative tools aim to promote socially valuable drugs and biologics through market incentives. The priority review voucher (PRV) program is the latest and most unique of these legislative tools aimed at encouraging the development of drugs for neglected diseases without burdening taxpayers. The Creating Hope Act—recently signed into law as part of the Food & Drug Administration Safety & Innovation Act—extends the PRV program to rare pediatric diseases. This Issue Brief argues that some provisions in this new legislation may result in undesirable collateral effects that could prevent the legislation from fulfilling its objective of encouraging investment in treatments for rare pediatric diseases